Advances in vaccine technology and their impact on managed care

Jonathan Mccullers, Jeffrey D. Dunn

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace. In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term. Who should and will pay for these anticipated improvements in health? How will this period of change be managed? This article describes the present "vaccine revolution" and attempts to answer these questions, which are becoming increasingly important in managed care.

Original languageEnglish (US)
JournalP and T
Volume33
Issue number1
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Managed Care Programs
Vaccines
Technology
Cost of Illness
Genetic Engineering
Health
Immunization
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Advances in vaccine technology and their impact on managed care. / Mccullers, Jonathan; Dunn, Jeffrey D.

In: P and T, Vol. 33, No. 1, 01.01.2008.

Research output: Contribution to journalReview article

@article{65c26253e8634b8db3689154da6fac00,
title = "Advances in vaccine technology and their impact on managed care",
abstract = "The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace. In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term. Who should and will pay for these anticipated improvements in health? How will this period of change be managed? This article describes the present {"}vaccine revolution{"} and attempts to answer these questions, which are becoming increasingly important in managed care.",
author = "Jonathan Mccullers and Dunn, {Jeffrey D.}",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
volume = "33",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "1",

}

TY - JOUR

T1 - Advances in vaccine technology and their impact on managed care

AU - Mccullers, Jonathan

AU - Dunn, Jeffrey D.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace. In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term. Who should and will pay for these anticipated improvements in health? How will this period of change be managed? This article describes the present "vaccine revolution" and attempts to answer these questions, which are becoming increasingly important in managed care.

AB - The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace. In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term. Who should and will pay for these anticipated improvements in health? How will this period of change be managed? This article describes the present "vaccine revolution" and attempts to answer these questions, which are becoming increasingly important in managed care.

UR - http://www.scopus.com/inward/record.url?scp=38949089241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949089241&partnerID=8YFLogxK

M3 - Review article

VL - 33

JO - P and T

JF - P and T

SN - 1052-1372

IS - 1

ER -